Risk factors of peptic ulcer in 4943 inpatients

Journal of Clinical Gastroenterology

Volumn 42, Issue 4, 2008, Pages 373-380

  Talamini, Giorgio ^a   Tommasi, Marina ^a   Amadei, Valeria ^a   Pajusco, Benedetta ^a   Fratucello, Anna ^a   Lechi, Alessandro ^a   Scroccaro, Giovanna ^a   Vantini, Italo ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Alcohol; Duodenal ulcer; Endoscopy; Epidemiology; Gastric ulcer; H 2 antagonists; Helicobacter pylori; Nonsteroidal anti inflammatory drugs; Proton pump inhibitors; Risk factors; Smoking

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ALCOHOL CONSUMPTION; ARTICLE; CIGARETTE SMOKING; DISEASE ASSOCIATION; DUODENUM ULCER; ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; PEPTIC ULCER; PRIORITY JOURNAL; RISK FACTOR; STOMACH ULCER;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DUODENAL ULCER; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HUMANS; INCIDENCE; ITALY; MALE; MIDDLE AGED; PEPTIC ULCER; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; STOMACH ULCER; TIME FACTORS;

EID: 41349098641     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3180318ac5     Document Type: Article

References (27)

1. Leontiadis GI, McIntyre L, Sharma VK, et al. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2006:CD002094.
2. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998;338:719-726.
3. Hawkey CJ. Non-steroidal anti-inflammatory drugs: who should receive prophylaxis? Aliment Pharmacol Ther. 2004;20(suppl 2):59-64.
4. Chancellor JV, Hunsche E, de Cruz E, et al. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics. 2001;19(suppl 1):59-75.
5. Moore A, Phillips C, Hunsche E, et al. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. Pharmacoeconomics. 2004;22:643-660.
6. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclooxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin, and combinations. Gut. 2006;55:1731-1738.
7. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365:475-481.
8. Xia B, Xia HH, Ma CW, et al. Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated dyspeptic patients in Hong Kong. Aliment Pharmacol Ther. 2005;22:243-249.
9. Perez-Aisa MA, Del Pino D, Siles M, et al. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2005;21:65-72.
10. Lassen A, Hallas J, de Muckadell OB. Complicated and uncomplicated peptic ulcers in a Danish County 1993-2002: a population-based cohort study. Am J Gastroenterol. 2006;101:945-953.
11. Delate T, Mager DE, Sheth J, et al. Clinical and financial outcomes associated with a proton pump inhibitor prior-authorization program in a Medicaid population. Am J Manag Care. 2005;11:29-36.
12. Peura DA. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med. 2004;117(suppl 5A):63S-71S.
13. Pilotto A, Franceschi M, Longoa MG, et al. Helicobacter pylori infection and the prevention of peptic ulcer with proton pump inhibitors in elderly subjects taking low-dose aspirin. Dig Liver Dis. 2004;36:666-670.
14. Guda NM, Noonan M, Kreiner MJ, et al. Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage? Am J Gastroenterol. 2004;99:1233-1237.
15. Mat Saad AZ, Collins N, Lobo MM, et al. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract. 2005;59:31-34.
16. Sturkenboom MC, Burke TA, Tangelder MJ, et al. Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2003;18:1137-1147.
17. Lucas LM, Gerrity MS, Anderson T. A practice-based approach for converting from proton pump inhibitors to less costly therapy. Eff Clin Pract. 2001;4:263-270.
18. McCarthy DM, McLaughlin TP, Griffis DL, et al. Impact of cotherapy with some proton pump inhibitors on medical claims among HMO patients already using other common drugs also cleared by cytochrome P450. Am J Ther. 2003;10:330-340.
19. 2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004;57:422-428.
20. Rostom A, Wells G, Tugwell P, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2000:CD002296.
21. Smalley WE, Ray WA, Daugherty JR, et al. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol. 1995;141:539-545.
22. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
23. Hawkey CJ, Laine L, Simon T, et al. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study. Gut. 2003;52:820-826.
24. Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol. 2004;159:23-31.
25. Gisbert JP, Legido J, Garcia-Sanz I, et al. Helicobacter pylori and perforated peptic ulcer prevalence of the infection and role of nonsteroidal anti-inflammatory drugs. Dig Liver Dis. 2004;36:116-120.
26. Aro P, Storskrubb T, Ronkainen J, et al. Peptic ulcer disease in a general adult population. Am J Epidemiol. 2006;163:1025-1034
27. Konturek SJ, Bielanski W, Plonka M, et al. Helicobacter pylori, non-steroidal anti-inflammatory drugs and smoking in risk pattern of gastroduodenal ulcers. Scand J Gastroenterol. 2003;38:923-930.